The active pharmaceutical ingredients market across the globe is witnessing growth due to factors such as the Increasing incidence of chronic diseases, rising prevalence of cancer, growing importance of generics, increase in abbreviated new drug applications (ANDA), and growing uptake of biopharmaceuticals.

“Key players are focusing on investing more on R&D activities for development of innovative therapeutics to cater to the unmet needs of the market.”

The active pharmaceutical ingredients market is segmented on the basis of type into innovative and generic APIs. The generic segment showcases lucrative growth potential and represents the new revenue pocket for the players during the forecast period. The high growth of this segment can be attributed to globally increasing healthcare expenditures, government initiatives to encourage adoption of generics to bring down healthcare costs, impending patent cliff and the increase in the number of ANDA approvals.

                                  Ask to Get the Discount on This Report@ http://bit.ly/2C4H1ys

“In the coming years, growth in the active pharmaceutical ingredients market is likely to be centered in Asia.”

This can be attributed to the increase in the growth in geriatric population, high prevalence of chronic and lifestyle diseases, increase in disposable income, prevalence of lifestyle- and age-related diseases, government efforts to reform healthcare and encourage adoption of generics, and growing market for merchant manufacturers in this region owing to the low labor and manufacturing costs.

The opportunities presented by the Asian market have the market is witnessing a large number of collaborations for the development of innovative products. For instance, in December 2015, WuXi AppTec (China) entered into a strategic alliance with MedImmune, a biologics research and development segment of AstraZeneca plc (U.K.), for the development of an innovative biologics portfolio in China.

On the other hand, big players in this region are focusing on expanding their manufacturing capacities to meet the growing demand of APIs. In this regards, in May 2016, Biocon Limited (India) invested UAD 158 million for expansion of its small molecule generics manufacturing facility in Bangalore, India. This invest also includes construction of a biopharmaceuticals manufacturing facility with a view to support company’s growing monoclonal antibodies portfolio.

The APIs market is competitive in nature, with several major players competing for market space. Some of the prominent players in the market include Pfizer Inc. (U.S.), Novartis International AG (Switzerland), Merck & Co. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Mylan, Inc. (U.S.), Boehringer Ingelheim (Germany), Sanofi (France), AbbVie (U.S.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), and GlaxoSmithKline plc (U.K.).

                         You Can Also Request the Bundle Reports@ http://bit.ly/2UCMqnO

Major Market Developments:

• In August 2016 , Pfizer entered into an agreement with AstraZeneca (U.K.) to acquire the development and commercialization rights of its small molecule anti-infectives business, primarily outside the United States.
• In June 2016, Novartis entered into a collaboration and licensing agreement with Xencor (U.S.), a biopharmaceutical company that develops engineered monoclonal antibodies. The purpose of this agreement was to develop bispecific antibodies for treating cancer.
• In February 2016, Sandoz acquired from Pfizer the rights for the development and commercialization of PF-06438179 (biosimilar infliximab) in the 28 countries that form the European Economic Area (EEA). This acquisition enables Novartis to broaden its immunology portfolio.

Critical questions which the report answers:

• Stringent regulatory requirements and unfavorable drug price control policies across various countries is a major concern in the industry, when will this scenario ease out?
• Emerging countries have immense opportunities for the growth of API manufacturers, will this scenario continue?

The following are the major objectives of the study:

• To define, describe, and forecast the global APIs market on the basis of type, type of manufacturer, type of synthesis, type of drug, therapeutic application, and region
• To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
• To strategically analyze micromarkets1 with respect to the individual growth trends, future prospects, and contributions to the overall market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)
• To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
• To track and analyze competitive developments such as partnerships, agreements, collaborations, joint ventures, alliances, mergers & acquisitions, approvals, expansions, and R&D activities in the global APIs market

Read the Detailed Research Study on “Active Pharmaceutical Ingredients/API Market – Global Forecast to 2021”, Here..!